News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
578,493 Results
Type
Article (48301)
Company Profile (119)
Press Release (530058)
Multimedia
Podcasts (164)
Webinars (23)
Section
Business (151051)
Career Advice (2446)
Deals (28831)
Drug Delivery (163)
Drug Development (72378)
Employer Resources (160)
FDA (16174)
Job Trends (12299)
News (275495)
Policy (30274)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2382)
Academic (1)
Accelerated approval (52)
Adcomms (40)
Allergies (162)
Alliances (38382)
ALS (206)
Alzheimer's disease (1851)
Antibody-drug conjugate (ADC) (455)
Approvals (16428)
Artificial intelligence (650)
Autoimmune disease (299)
Automation (47)
Bankruptcy (317)
Best Places to Work (9361)
BIOSECURE Act (23)
Biosimilars (223)
Biotechnology (72)
Bladder cancer (199)
Brain cancer (70)
Breast cancer (701)
Cancer (5591)
Cardiovascular disease (490)
Career advice (2081)
Career pathing (47)
CAR-T (301)
CDC (75)
Celiac Disease (2)
Cell therapy (873)
Cervical cancer (44)
Clinical research (62974)
Collaboration (1845)
Company closure (7)
Compensation (1410)
Complete response letters (102)
COVID-19 (2771)
CRISPR (106)
C-suite (1059)
Cystic fibrosis (153)
Data (7557)
Decentralized trials (3)
Denatured (36)
Depression (178)
Dermatology (86)
Diabetes (564)
Diagnostics (5782)
Digital health (45)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (298)
Drug pricing (239)
Drug shortages (34)
Duchenne muscular dystrophy (295)
Earnings (65543)
Editorial (77)
Employer branding (20)
Employer resources (142)
Events (86825)
Executive appointments (998)
FDA (19895)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (33)
Funding (1522)
Gene editing (232)
Generative AI (59)
Gene therapy (735)
GLP-1 (1185)
Government (4289)
Grass and pollen (8)
Guidances (398)
Healthcare (15157)
HIV (82)
Huntington's disease (60)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (100)
Immunology and inflammation (335)
Immuno-oncology (91)
Indications (180)
Infectious disease (3102)
Inflammatory bowel disease (215)
Inflation Reduction Act (14)
Influenza (125)
Intellectual property (278)
Interviews (460)
IPO (14338)
IRA (58)
Job creations (3218)
Job search strategy (1689)
JPM (69)
Kidney cancer (21)
Labor market (102)
Layoffs (641)
Leadership (49)
Legal (7119)
Liver cancer (99)
Longevity (26)
Lung cancer (723)
Lymphoma (408)
Machine learning (56)
Management (52)
Manufacturing (984)
MASH (202)
Medical device (11796)
Medtech (11906)
Mergers & acquisitions (15653)
Metabolic disorders (1579)
mRNA (234)
Multiple sclerosis (171)
NASH (23)
Neurodegenerative disease (432)
Neuropsychiatric disorders (120)
Neuroscience (3360)
Neurotech (2)
NextGen: Class of 2026 (5073)
Non-profit (3233)
Now hiring (34)
Obesity (787)
Opinion (312)
Ovarian cancer (207)
Pain (244)
Pancreatic cancer (299)
Parkinson's disease (366)
Partnered (27)
Patents (586)
Patient recruitment (645)
Peanut (59)
People (46130)
Pharmaceutical (34)
Pharmacy benefit managers (34)
Phase 1 (19211)
Phase 2 (27397)
Phase 3 (21789)
Pipeline (8494)
Policy (380)
Postmarket research (2262)
Preclinical (8087)
Press Release (28)
Prostate cancer (313)
Psychedelics (67)
Radiopharmaceuticals (300)
Rare diseases (1139)
Real estate (4445)
Recruiting (65)
Regulatory (24389)
Reports (49)
Research institute (2179)
Resumes & cover letters (408)
Rett syndrome (39)
RNA editing (22)
RSV (83)
Schizophrenia (185)
Series A (263)
Series B (197)
Service/supplier (8)
Sickle cell disease (113)
Special edition (30)
Spinal muscular atrophy (168)
Sponsored (52)
Startups (2983)
State (1)
Stomach cancer (21)
Supply chain (128)
Tariffs (104)
The Weekly (126)
Vaccines (1186)
Venture capital (119)
Weight loss (556)
Women's health (109)
Worklife (24)
Date
Today (43)
Last 7 days (538)
Last 30 days (3107)
Last 365 days (28533)
2026 (12388)
2025 (28652)
2024 (31768)
2023 (35409)
2022 (45658)
2021 (49253)
2020 (46177)
2019 (36929)
2018 (28020)
2017 (28528)
2016 (26586)
2015 (29129)
2014 (22764)
2013 (18738)
2012 (19952)
2011 (20481)
2010 (18575)
Location
Africa (707)
Alabama (75)
Alaska (6)
Arizona (272)
Arkansas (13)
Asia (33848)
Australia (6098)
California (12499)
Canada (3017)
China (1133)
Colorado (487)
Connecticut (553)
Delaware (377)
Europe (83062)
Florida (1896)
Georgia (383)
Hawaii (4)
Idaho (41)
Illinois (924)
India (75)
Indiana (501)
Iowa (23)
Japan (520)
Kansas (112)
Kentucky (38)
Louisiana (31)
Maine (79)
Maryland (1501)
Massachusetts (9007)
Michigan (303)
Minnesota (664)
Mississippi (5)
Missouri (133)
Montana (18)
Nebraska (23)
Nevada (130)
New Hampshire (65)
New Jersey (3316)
New Mexico (16)
New York (3206)
North Carolina (1585)
North Dakota (8)
Northern California (6357)
Ohio (340)
Oklahoma (18)
Oregon (34)
Pennsylvania (2404)
Puerto Rico (22)
Rhode Island (33)
South America (1066)
South Carolina (83)
South Dakota (2)
Southern California (4936)
Tennessee (182)
Texas (1910)
United States (43461)
Utah (312)
Virginia (302)
Washington D.C. (73)
Washington State (969)
West Virginia (4)
Wisconsin (127)
Wyoming (1)
578,493 Results for "leiter s compounding".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Weight loss
Lilly Flags ‘Concerning’ Impurities in Compounded Tirzepatide
Combining tirzepatide with vitamin B12, a common additive in compounded versions of the drug, yields an impurity that could alter the drug’s toxicity profile and pose safety risks to patients, the company said in an open letter.
March 12, 2026
·
2 min read
·
Tristan Manalac
Supply chain
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s
Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products were linked with multiple ER visits.
March 4, 2026
·
2 min read
·
Nick Paul Taylor
FDA
FDA mulls compounding for peptides previously flagged over safety risks
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns.
April 16, 2026
·
1 min read
·
Nick Paul Taylor
Legal
Compounder Sues Lilly, Novo, Claims Coordinated Crackdown
Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers in exclusive partnerships, disallowing them from offering compounded versions of GLP-1 medicines.
January 15, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
The agency flagged several violations at a compounding pharmacy owned by Hims & Hers, including “infestation by rodents, birds insects, and other vermin.”
February 10, 2026
·
2 min read
·
Tristan Manalac
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
A lawsuit and FDA warning ensued after Hims & Hers launched a compounded version of Novo Nordisk’s new obesity pill, more Big Pharma report earnings—including from weight loss rivals Novo and Eli Lilly—and the gene therapy space sees another rejection.
February 11, 2026
·
1 min read
·
Jef Akst
GLP-1
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill
Novo Nordisk has also spoken out strongly against Hims & Hers’ compounded Wegovy pill, with CEO Maziar Mike Doustdar telling investors the knockoff version is a waste of money.
February 6, 2026
·
1 min read
·
Tristan Manalac
Press Releases
PharmaTher’s Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher’s PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an attractive solution for compounding pharmacies, hospitals, research institutions, and commercial partners
April 20, 2026
·
8 min read
Podcast
Kennedy’s Vaccine Agenda Stalled, Structure’s ‘Competitive’ Obesity Pill, Novo’s Warning Letter
Heath Secretary Robert F. Kennedy Jr.’s efforts to overhaul vaccine policy are likely illegal, a Massachusetts District Court Judge ruled; Structure’s GLP-1 weight loss pill succeeds in Phase 2 while Rhythm’s Phase 3 basket trial fails to find the beat; Eli Lilly warns of potential safety risks of taking compounded tirzepatide, and Novo Nordisk is hit with an FDA warning letter regarding adverse events potentially linked to Ozempic.
March 18, 2026
·
1 min read
·
Heather McKenzie
Press Releases
Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent
January 1, 2026
·
2 min read
1 of 57,850
Next